AlphaQuest LLC Acquires 3,297 Shares of Alphatec Holdings, Inc. $ATEC

AlphaQuest LLC grew its holdings in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) by 37.8% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 12,012 shares of the medical technology company’s stock after acquiring an additional 3,297 shares during the period. AlphaQuest LLC’s holdings in Alphatec were worth $133,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the business. Nuveen LLC bought a new position in Alphatec during the 1st quarter worth $135,874,000. MetLife Investment Management LLC grew its position in shares of Alphatec by 1,818.5% in the 1st quarter. MetLife Investment Management LLC now owns 1,213,943 shares of the medical technology company’s stock valued at $12,309,000 after buying an additional 1,150,669 shares during the last quarter. Driehaus Capital Management LLC acquired a new stake in shares of Alphatec in the first quarter valued at about $10,398,000. Motley Fool Wealth Management LLC acquired a new stake in shares of Alphatec in the first quarter valued at about $9,070,000. Finally, American Century Companies Inc. raised its position in shares of Alphatec by 16.9% during the first quarter. American Century Companies Inc. now owns 5,830,031 shares of the medical technology company’s stock worth $59,117,000 after acquiring an additional 840,974 shares during the last quarter. Institutional investors own 66.35% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. JPMorgan Chase & Co. began coverage on shares of Alphatec in a research report on Friday, October 24th. They set an “overweight” rating and a $19.00 target price for the company. Barclays increased their price objective on shares of Alphatec from $22.00 to $23.00 and gave the stock an “overweight” rating in a research report on Monday. Needham & Company LLC boosted their target price on shares of Alphatec from $16.00 to $22.00 and gave the company a “buy” rating in a report on Friday, October 31st. HC Wainwright upped their price target on shares of Alphatec from $20.00 to $24.00 and gave the company a “buy” rating in a research report on Friday. Finally, Canaccord Genuity Group lifted their price objective on Alphatec from $20.00 to $25.00 and gave the stock a “buy” rating in a research report on Friday. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $22.11.

Alphatec Stock Up 0.7%

Shares of NASDAQ ATEC opened at $19.42 on Wednesday. The company has a quick ratio of 1.77, a current ratio of 2.88 and a debt-to-equity ratio of 23.22. The firm has a market cap of $2.87 billion, a PE ratio of -17.19 and a beta of 1.05. The company’s fifty day simple moving average is $15.41 and its 200 day simple moving average is $13.41. Alphatec Holdings, Inc. has a 12-month low of $7.87 and a 12-month high of $20.15.

Alphatec (NASDAQ:ATEC) last announced its quarterly earnings data on Thursday, October 30th. The medical technology company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.09. The company had revenue of $196.50 million for the quarter, compared to analyst estimates of $182.78 million. Alphatec’s revenue for the quarter was up 30.4% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.28) EPS. Alphatec has set its FY 2025 guidance at EPS. As a group, sell-side analysts forecast that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.

Insider Buying and Selling at Alphatec

In other news, CEO Patrick Miles sold 300,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $15.73, for a total transaction of $4,719,000.00. Following the completion of the sale, the chief executive officer owned 5,564,078 shares in the company, valued at $87,522,946.94. The trade was a 5.12% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Craig E. Hunsaker sold 100,000 shares of the stock in a transaction on Friday, October 31st. The stock was sold at an average price of $19.95, for a total value of $1,995,000.00. Following the completion of the transaction, the executive vice president owned 1,289,142 shares in the company, valued at approximately $25,718,382.90. This represents a 7.20% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 788,125 shares of company stock worth $12,604,027 in the last quarter. Company insiders own 20.90% of the company’s stock.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.